JP2014503576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503576A5 JP2014503576A5 JP2013550908A JP2013550908A JP2014503576A5 JP 2014503576 A5 JP2014503576 A5 JP 2014503576A5 JP 2013550908 A JP2013550908 A JP 2013550908A JP 2013550908 A JP2013550908 A JP 2013550908A JP 2014503576 A5 JP2014503576 A5 JP 2014503576A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- optionally substituted
- pyridyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 claims 3
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- -1 pyran-4-yl Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- CTBSIWZADWNGPL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1Cl CTBSIWZADWNGPL-UHFFFAOYSA-N 0.000 claims 1
- DGTJUXLZPAKEDG-UHFFFAOYSA-N 1-(2-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=CC=C1C1=NN=C2N1C1=CC=CC=C1N=C2C DGTJUXLZPAKEDG-UHFFFAOYSA-N 0.000 claims 1
- FDXFIVYCNRJKCU-UHFFFAOYSA-N 2-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1O FDXFIVYCNRJKCU-UHFFFAOYSA-N 0.000 claims 1
- PKFKCXQPEAGAHL-UHFFFAOYSA-N 2-methoxy-6-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenol Chemical compound COC1=CC=CC(C=2N3C4=CC=CC=C4N=C(C)C3=NN=2)=C1O PKFKCXQPEAGAHL-UHFFFAOYSA-N 0.000 claims 1
- PDPJEMXSHLGRFT-UHFFFAOYSA-N 4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC(N)=CC=C1Cl PDPJEMXSHLGRFT-UHFFFAOYSA-N 0.000 claims 1
- KXSGJAHZGIIUIR-UHFFFAOYSA-N 4-methoxy-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound COC1=CC=C(N)C=C1C1=NN=C2N1C1=CC=CC=C1N=C2C KXSGJAHZGIIUIR-UHFFFAOYSA-N 0.000 claims 1
- QKWYLCALFFTEAL-UHFFFAOYSA-N 4-methyl-1-(2-nitrophenyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1[N+]([O-])=O QKWYLCALFFTEAL-UHFFFAOYSA-N 0.000 claims 1
- WULGHPGREVSKPP-UHFFFAOYSA-N 4-methyl-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)aniline Chemical compound CC1=CC=C(N)C=C1C1=NN=C2N1C1=CC=CC=C1N=C2C WULGHPGREVSKPP-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000035976 Developmental Disabilities Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical group CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 Cc1nnc2[n]1c1c(*)c(*)c(*)c(*)c1nc2* Chemical compound Cc1nnc2[n]1c1c(*)c(*)c(*)c(*)c1nc2* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437848P | 2011-01-31 | 2011-01-31 | |
| US61/437,848 | 2011-01-31 | ||
| PCT/EP2012/051546 WO2012104293A1 (en) | 2011-01-31 | 2012-01-31 | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503576A JP2014503576A (ja) | 2014-02-13 |
| JP2014503576A5 true JP2014503576A5 (https=) | 2015-03-19 |
| JP6027547B2 JP6027547B2 (ja) | 2016-11-16 |
Family
ID=45833359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550908A Active JP6027547B2 (ja) | 2011-01-31 | 2012-01-31 | ホスホジエステラーゼの阻害薬としての（１，２，４）トリアゾロ［４，３−ａ］キノキサリン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9540379B2 (https=) |
| EP (1) | EP2670754B1 (https=) |
| JP (1) | JP6027547B2 (https=) |
| KR (1) | KR20140019342A (https=) |
| CN (1) | CN103459395A (https=) |
| AR (1) | AR085099A1 (https=) |
| AU (1) | AU2012213471B2 (https=) |
| BR (1) | BR112013019354A2 (https=) |
| CA (1) | CA2824929A1 (https=) |
| CL (1) | CL2013002003A1 (https=) |
| CO (1) | CO6811848A2 (https=) |
| EA (1) | EA023792B1 (https=) |
| EC (1) | ECSP13012824A (https=) |
| GE (1) | GEP20156333B (https=) |
| IL (1) | IL226826A (https=) |
| MA (1) | MA34844B1 (https=) |
| MX (1) | MX2013008667A (https=) |
| PE (1) | PE20141023A1 (https=) |
| PH (1) | PH12013501355A1 (https=) |
| SG (1) | SG192210A1 (https=) |
| TN (1) | TN2013000325A1 (https=) |
| TW (1) | TWI535718B (https=) |
| UA (1) | UA111963C2 (https=) |
| UY (1) | UY33888A (https=) |
| WO (1) | WO2012104293A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013033375B1 (pt) * | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| WO2013034758A1 (en) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| JP2014526453A (ja) * | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| WO2013034755A1 (en) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| HK1206250A1 (en) | 2012-06-26 | 2016-01-08 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2014139983A1 (en) | 2013-03-13 | 2014-09-18 | H. Lundbeck A/S | [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors |
| EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
| DK3134413T3 (da) | 2014-04-23 | 2019-10-14 | Dart Neuroscience Cayman Ltd | Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer |
| US10239882B2 (en) | 2014-11-05 | 2019-03-26 | Dart Neuroscience (Cayman) Ltd. | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| US10300064B2 (en) | 2014-12-06 | 2019-05-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| WO2017165311A1 (en) * | 2016-03-21 | 2017-09-28 | Perlstein Lab Pbc | Fused heterocyclic organic compounds and uses thereof |
| CN106212487B (zh) * | 2016-07-28 | 2018-11-13 | 浙江工业大学 | 一种含甲氧基苯并吡嗪结构的1,2,4-三唑衍生物作为杀菌剂的应用 |
| AU2018371216B2 (en) | 2017-11-23 | 2024-09-19 | Oslo University Hospital Hf | Treatment of tachycardia |
| CN116903569B (zh) * | 2023-07-06 | 2025-07-11 | 常州大学 | 作为磷酸二酯酶2抑制剂的香豆素-查尔酮杂合类衍生物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153196A (en) | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| BRPI0407926A (pt) * | 2003-03-27 | 2006-02-21 | Pfizer Prod Inc | 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas |
| JP2006524638A (ja) * | 2003-04-30 | 2006-11-02 | メルク フロスト カナダ リミテツド | ８−（３−ビアリール）フェニルキノリン系ホスホジエステラーゼ−４阻害薬 |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| ATE387446T1 (de) | 2003-12-16 | 2008-03-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| AU2005279221C9 (en) | 2004-09-02 | 2012-08-23 | Takeda Gmbh | Triazolophthalazines |
| BRPI0606379A2 (pt) | 2005-01-05 | 2009-06-23 | Nycomed Gmbh | triazolftalazinas |
| EP1874775B1 (en) | 2005-01-05 | 2012-10-10 | Nycomed GmbH | Triazolophthalazines as pde2-inhibitors |
| BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| JP2009523820A (ja) | 2006-01-23 | 2009-06-25 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼの三環系抑制剤 |
| WO2007121319A2 (en) | 2006-04-14 | 2007-10-25 | University Of California | Compostions and methods for determining and predicting treatment responses for depression and anxiety |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| KR20100110804A (ko) | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| TW201024297A (en) | 2008-09-10 | 2010-07-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| US20100120762A1 (en) | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2010104933A1 (en) | 2009-03-11 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010138833A1 (en) * | 2009-05-29 | 2010-12-02 | Wyeth | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 |
| EP2266985A1 (en) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tricyclic Pyrimidine Derivatives as Wnt antagonists |
| CN107141309A (zh) | 2011-01-11 | 2017-09-08 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| JP2014526453A (ja) | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| HK1206250A1 (en) | 2012-06-26 | 2016-01-08 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
-
2012
- 2012-01-30 US US13/361,002 patent/US9540379B2/en active Active
- 2012-01-31 AU AU2012213471A patent/AU2012213471B2/en not_active Ceased
- 2012-01-31 BR BR112013019354A patent/BR112013019354A2/pt not_active IP Right Cessation
- 2012-01-31 PE PE2013001585A patent/PE20141023A1/es not_active Application Discontinuation
- 2012-01-31 CA CA2824929A patent/CA2824929A1/en not_active Abandoned
- 2012-01-31 TW TW101103150A patent/TWI535718B/zh not_active IP Right Cessation
- 2012-01-31 GE GEAP201213211A patent/GEP20156333B/en unknown
- 2012-01-31 WO PCT/EP2012/051546 patent/WO2012104293A1/en not_active Ceased
- 2012-01-31 MX MX2013008667A patent/MX2013008667A/es active IP Right Grant
- 2012-01-31 CN CN2012800157168A patent/CN103459395A/zh active Pending
- 2012-01-31 EA EA201300871A patent/EA023792B1/ru not_active IP Right Cessation
- 2012-01-31 AR ARP120100303A patent/AR085099A1/es unknown
- 2012-01-31 EP EP12708774.0A patent/EP2670754B1/en active Active
- 2012-01-31 UY UY0001033888A patent/UY33888A/es not_active Application Discontinuation
- 2012-01-31 UA UAA201310356A patent/UA111963C2/uk unknown
- 2012-01-31 MA MA36142A patent/MA34844B1/fr unknown
- 2012-01-31 SG SG2013057815A patent/SG192210A1/en unknown
- 2012-01-31 KR KR1020137023101A patent/KR20140019342A/ko not_active Ceased
- 2012-01-31 JP JP2013550908A patent/JP6027547B2/ja active Active
- 2012-01-31 PH PH1/2013/501355A patent/PH12013501355A1/en unknown
-
2013
- 2013-06-09 IL IL226826A patent/IL226826A/en not_active IP Right Cessation
- 2013-07-08 CL CL2013002003A patent/CL2013002003A1/es unknown
- 2013-07-29 CO CO13179130A patent/CO6811848A2/es not_active Application Discontinuation
- 2013-07-29 TN TNP2013000325A patent/TN2013000325A1/fr unknown
- 2013-08-13 EC EC2013012824A patent/ECSP13012824A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503576A5 (https=) | ||
| Paik et al. | Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| JP2015523406A5 (https=) | ||
| EA201001181A1 (ru) | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| Chaudhary et al. | Stable tricyclic antitubercular ozonides derived from artemisinin | |
| JP6421185B2 (ja) | ベンゾイミダゾール−プロリン誘導体の使用 | |
| JP2014521662A5 (https=) | ||
| JP2017524005A5 (https=) | ||
| JP2019532079A5 (https=) | ||
| EA201500402A1 (ru) | Гетероароматические соединения в качестве лигандов допамина d1 | |
| JP2009538852A5 (https=) | ||
| JP2009538853A5 (https=) | ||
| JP2010520264A5 (https=) | ||
| CN101516881A (zh) | 2-芳基-6-苯基-咪唑并[1,2-α]吡啶衍生物、其制备和治疗用途 | |
| JP2022141835A (ja) | フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 | |
| Le Manach et al. | A novel pyrazolopyridine with in vivo activity in Plasmodium berghei-and Plasmodium falciparum-infected mouse models from structure–activity relationship studies around the core of recently identified antimalarial imidazopyridazines | |
| JP2009538910A5 (https=) | ||
| JP2015506382A5 (https=) | ||
| TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| JP2014510147A5 (https=) | ||
| Liu et al. | [11C] CHDI-626, a PET tracer candidate for imaging mutant Huntingtin aggregates with reduced binding to AD pathological proteins | |
| RU2017106100A (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2 | |
| RU2009142997A (ru) | 4-алкоксипиридазиновые производные в качестве быстро диссоциирующихся антагонистов рецептора 2 допамина |